Product Description
please call me , to know more
AI Product Description
*The following content is generated by AI and is for reference only.
Abiraterone acetate is a potent oral prodrug of abiraterone, serving as a cornerstone therapy in the management of metastatic castration-resistant prostate cancer (mCRPC). Chemically classified as an androgen biosynthesis inhibitor, it functions by irreversibly blocking the enzyme CYP17A1 (17α-hydroxylase/17,20-lyase). This specific enzymatic inhibition effectively halts the production of androgens, including testosterone and dihydrotestosterone, both within the testes and crucially within the adrenal glands and tumor tissue itself. By depriving prostate cancer cells of these essential growth signals, the drug significantly slows disease progression and extends overall survival in patients who have previously received docetaxel chemotherapy or are newly diagnosed with mCRPC.
The molecular formula of Abiraterone acetate is C₂₄H₃₁NO₂, and its unique Chemical Abstracts Service (CAS) registry number is 154229-19-7. As an acetate ester prodrug, it exhibits improved bioavailability compared to the active parent compound, abiraterone, allowing for effective oral administration. In clinical practice, it is almost exclusively administered in combination with low-dose prednisone or prednisolone. This corticosteroid co-administration is critical to manage the compensatory rise in mineralocorticoids that occurs when CYP17A1 is inhibited, thereby preventing adverse effects such as hypertension, hypokalemia, and fluid retention.
Therapeutic indications primarily focus on adult males with mCRPC, whether they are hormone-naïve or have progressed after prior treatments. The drug has demonstrated remarkable efficacy in reducing PSA levels and delaying radiographic progression. While generally well-tolerated, monitoring for hepatotoxicity and cardiovascular events is standard protocol during treatment. With its mechanism targeting the root hormonal drivers of prostate cancer, Abiraterone acetate represents a significant advancement in precision oncology, offering a vital option for improving quality of life and survival outcomes in advanced prostate cancer cases where traditional therapies may no longer be effective.